This inventor holds 3 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignee: University of Virginia Patent Foundation. Active years: 2017-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017-2024
Title: Innovations by Rahul Sharma in Autoimmune and Inflammatory Disease Treatments.
Introduction
Rahul Sharma is an accomplished inventor based in Charlottesville, VA. He has made significant contributions to the field of medical research, particularly in the treatment of autoimmune and inflammatory diseases. With a total of 3 patents, his work focuses on innovative therapies that leverage the properties of interleukins.
Latest Patents
Sharma's latest patents include compositions and methods for the treatment of autoimmune and inflammatory diseases and disorders. One notable patent discloses a novel fusion peptide of IL-2 and IL-33, which comprises biologically active domains of both interleukins. This fusion protein is designed to be effective in preventing or treating various diseases and disorders, including autoimmune conditions and inflammation. The application highlights the potential of combination therapies using IL-2 and IL-33, as well as the IL233 fusion protein, to alleviate symptoms and treat underlying conditions.
Career Highlights
Rahul Sharma is associated with the University of Virginia Patent Foundation, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on therapeutic strategies for complex diseases.
Collaborations
Sharma collaborates with Mark D Okusa, a fellow researcher, to further explore the applications of his patented technologies in clinical settings.
Conclusion
Rahul Sharma's innovative work in the field of autoimmune and inflammatory disease treatments showcases his commitment to advancing medical science. His contributions through patents and collaborations are paving the way for new therapeutic options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
